Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 5
Submit an article Journal homepage
365
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set

Monica ZiffUniversity College London Hospitals NHS Foundation Trust, London, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7094-2779View further author information
ORCID Icon,
Gabrielle LawsonUniversity College London Hospitals NHS Foundation Trust, London, UKView further author information
,
Dunnya De-SilvaUniversity College London Hospitals NHS Foundation Trust, London, UKView further author information
,
Simon CheesmanUniversity College London Hospitals NHS Foundation Trust, London, UKView further author information
,
Charalampia KyriakouUniversity College London Hospitals NHS Foundation Trust, London, UKORCID Iconhttps://orcid.org/0000-0002-7297-503XView further author information
ORCID Icon,
Shameem MahmoodUniversity College London Hospitals NHS Foundation Trust, London, UKView further author information
,
Xenofon PapanikolaouUniversity College London Hospitals NHS Foundation Trust, London, UKView further author information
,
Neil RabinUniversity College London Hospitals NHS Foundation Trust, London, UKView further author information
,
Sajitha SachchithananthanUniversity College London Hospitals NHS Foundation Trust, London, UKView further author information
,
Jonathan SiveUniversity College London Hospitals NHS Foundation Trust, London, UKView further author information
,
Ashutosh WechalekarUniversity College London Hospitals NHS Foundation Trust, London, UKORCID Iconhttps://orcid.org/0000-0002-4406-7237View further author information
ORCID Icon,
Kwee YongUniversity College London Hospitals NHS Foundation Trust, London, UKORCID Iconhttps://orcid.org/0000-0002-6487-276XView further author information
ORCID Icon &
Rakesh PopatUniversity College London Hospitals NHS Foundation Trust, London, UKORCID Iconhttps://orcid.org/0000-0001-6553-4618View further author information
ORCID Icon show all
Pages 1243-1246 | Received 25 Nov 2020, Accepted 09 Dec 2020, Published online: 13 Jan 2021

References

  • Shah JJ, Abonour R, Gasparetto C, et al. Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes. Clin Lymphoma Myeloma Leuk. 2017;17(9):575–583.
  • Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621–1634.
  • Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346.
  • Thakurta A, Ortiz M, Blecua P, et al. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma. Blood. 2019;133(11):1217–1221.
  • Goldschmidt H, Lokhorst HM, Mai EK, et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia. 2018;32(2):383–390.
  • Collins R, Bowman L, Landray M, et al. The magic of randomization versus the myth of real-world evidence. N Engl J Med. 2020;382(7):674–678.
  • Terpos E, Ramasamy K, Maouche N, et al. Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Ann Hematol. 2020;99(5):1049–1061.
  • Varga G, Nagy Z, Demeter J, et al. Real world efficacy and safety results of ixazomib lenalidomide and dexamethasone combination in relapsed/refractory multiple myeloma: data collected from the hungarian ixazomib named patient program. Pathol Oncol Res. 2019;25(4):1615–1620.
  • Richardson PG, San Miguel JF, Moreau P, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8(11):109.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.